Combination Cyclophosphamide and Rituximab to Minimize Glucocorticoid Use in Antineutrophil Cytoplasm Antibody–Associated Vasculitis

Combination Cyclophosphamide and Rituximab to Minimize Glucocorticoid Use in Antineutrophil Cytoplasm Antibody–Associated Vasculitis

Introduction: The optimal duration of immunosuppressive therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is uncertain. Glucocorticoids are a mainstay of treatment but are associated with significant morbidity. Here, we describe outcomes of a cohort of patients treated...

Full description

Saved in:
Bibliographic Details
Main Authors: Tania Salehi, Gavin B. Chapman, Tariq E. Farrah, Fiona A. Chapman, Dan Pugh, Robert W. Hunter, Neeraj Dhaun
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Kidney International Reports
Subjects:
ANCA vasculitis
cyclophosphamide
glucocorticoids
induction treatment
rituximab
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024925002554
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items